News

CarnoSyn® Brands Unveils TriBsyn™ at ESPEN Congress

CarnoSyn® Brands Unveils TriBsyn™ at ESPEN Congress

CarnoSyn® Brands to Showcase TriBsyn™ at the ESPEN Congress

Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands are excited to present TriBsyn™ at the upcoming ESPEN Congress on Clinical Nutrition & Metabolism. This congress is a key event where companies can highlight and discuss innovative scientific developments in nutrition and metabolism, fostering collaboration among healthcare professionals, including physicians, dietitians, and pharmacists.

Advancements in Clinical Nutrition

The teams from NAI and CarnoSyn® Brands welcome attendees to visit them at stand #16, where they will share the latest clinical research on TriBsyn™, a patent-pending formulation aimed at improving the bioavailability and absorption of beta-alanine. This cutting-edge solution effectively reduces the common sensory side effects that can occur with higher doses of beta-alanine, making it accessible to a broader audience—particularly older adults and those focused on wellness.

Key Features of TriBsyn™

TriBsyn™ opens up opportunities for previously underserved markets, providing solutions for wellness enthusiasts and nutritional supplement advocates alike. Attendees will have the opportunity to discover the product's unique formulation, which caters to a diverse range of demographics, from athletes to health-conscious seniors.

A Breakthrough in the Supplement Industry

Aaron Starr, Vice President of CarnoSyn® Brands, expressed his excitement about showcasing TriBsyn™ at the ESPEN Congress. He highlighted the increasing demand for effective solutions that support healthy aging and wellness, noting that this proprietary carnosine booster marks a significant step forward in dietary supplements and medical food formulations aimed at enhancing muscle vitality, cognitive performance, and anti-aging benefits.

Future Events After ESPEN

Following the ESPEN Congress, the CarnoSyn® Brands team will also participate in the 20th European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain. Their ongoing involvement in prominent health and nutrition events underscores their dedication to engaging with the medical community while sharing vital research findings and product innovations.

About CarnoSyn® Brands

CarnoSyn® Brands is known for its three clinically validated, patented ingredients, available exclusively through Natural Alternatives International, Inc. These include CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and the newly introduced TriBsyn™ powder. In recent years, CarnoSyn® beta-alanine has reached significant regulatory milestones, including New Dietary Ingredient (NDI) status from the FDA and Self-Affirmed Generally Recognized as Safe (GRAS) status.

The Importance of TriBsyn™

This innovative 'paresthesia-free' TriBsyn™ formula allows NAI to broaden its product offerings within dietary supplements, encompassing both medical and fortified food products. The launch of this new product is expected to resonate with consumers seeking effective ingredients to aid their health and wellness objectives.

About Natural Alternatives International, Inc. (NAI)

NAI is a leading entity in the formulation, manufacturing, and marketing of nutritional supplements. The company's collaborative approach promotes innovation in nutritional products and services, providing a wide array of scientific research support, proprietary ingredients, product formulation, and marketing management. Customers can depend on NAI for packaging and delivery system design, as well as regulatory review and international product registration assistance.

Contact Information

For any inquiries, please contact:

Renee Michaelson
Director of Global Marketing
NAI/CarnoSyn® Brands
(760) 736-7700
info@nai-online.com

Frequently Asked Questions

What is TriBsyn™?

TriBsyn™ is a new, patent-pending formulation designed to enhance the bioavailability of beta-alanine while reducing the side effects commonly associated with its use.

Where can I learn more about CarnoSyn® Brands?

You can find more information on CarnoSyn® Brands' official website and at their exhibit during various nutrition conferences.

What events will CarnoSyn® Brands be attending?

CarnoSyn® Brands will be exhibiting at the ESPEN Congress and will also attend the European Geriatric Medicine Society (EuGMS) Congress.

What is the significance of beta-alanine?

Beta-alanine is a widely used supplement that enhances performance by reducing fatigue and improving muscle endurance.

How can TriBsyn™ benefit older adults?

TriBsyn™ is especially beneficial for older adults who want to support muscle vitality and cognitive function as they age.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 30

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 25

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 45

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 59

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 41

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 38

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 34

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading

Top 5 Most Recently Viewed Articles

Genesys Celebrates Global Recognition as a Top Workplace

Updated Category News Views 50

Genesys Achieves Global Recognition for Workplace Excellence Genesys, a renowned leader in AI-driven experience orchestration, has been proudly certified as a Great Place to Work. This significant accomplishment reflects the overwhelming sentiment from its employees, with a remarkable 90% affirming that Genesys is indeed a fantastic workplace. This statistic represents a...

Continue Reading
Class Action Alert for Twitter Stockholders: Important Updates

Updated Category News Views 198

Understanding the Class Action Lawsuit for Twitter, Inc. Stockholders A significant class action lawsuit has been initiated for individuals and entities who traded Twitter, Inc. stock or options during a specified period. This legal action has garnered substantial attention as it affects numerous investors who believe they suffered losses due to alleged misconduct. Key...

Continue Reading
Rhythm Pharmaceuticals Advances IMCIVREE® for Young Patients

Updated Category News Views 180

Rhythm Pharmaceuticals Receives FDA Acceptance for Priority Review Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company, has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide). This application has been designated for Priority Review by the FDA, which suggests that patients may gain timely...

Continue Reading
Understanding Market Trends Impacting NCR Atleos Corp's Future

Updated Category News Views 59

Market Sentiment Surrounding NCR Atleos Corp NCR Atleos Corp (NYSE: NATL) has recently caught the attention of investors as its short interest percentage has experienced a notable increase. Currently, approximately 3.76% of the company's shares have been sold short, which translates to about 3.01 million shares. This figure indicates that roughly 6.35% of all regular...

Continue Reading
Leslie’s, Inc. Reports Q2 Fiscal 2025 Earnings and Key Insights

Updated Category News Views 346

Financial Highlights from Leslie’s, Inc. In light of recent developments, Leslie’s, Inc. (NASDAQ: LESL), the premier name in pool and spa care in the U.S., has unveiled its financial results for the second quarter of fiscal year 2025. The company is dedicated to serving both residential and professional customers with quality products and exceptional service. CEO...

Continue Reading